Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Published in 2015 - Ann Oncol (2015) 26 (8): 1573-1588. doi: 10.1093/annonc/mdv187
Authors: W. E. E. Eberhardt, D. De Ruysscher, W. Weder, C. Le Péchoux, P. De Leyn, H. Hoffmann, V. Westeel, R. Stahel, E. Felip, S. Peters

This report from the 2nd ESMO Consensus Conference on Lung Cancer complements existing guidelines and provides recommendations by international experts on guidance substaging stage III NSCLC for decision making, optimal diagnostic work-up, most relevant comorbidities, optimal multimodality combinations for the different substages, optimal chemotherapy, radiotherapy and surgery regimens, patient characteristics to take into account in treatment decisions and the place for targeted agents in stage III NSCLC.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.